Customize your JAMA Network experience by selecting one or more topics from the list below.
Metformin has been proffered as a therapy for adolescent obesity, although long-term controlled studies have not been reported.
To test the hypothesis that 48 weeks of daily metformin hydrochloride extended release (XR) therapy will reduce body mass index (BMI) in obese adolescents, as compared with placebo.
Multicenter, randomized, double-blind, placebo-controlled clinical trial.
The 6 centers of the Glaser Pediatric Research Network from October 2003 to August 2007.
Obese (BMI≥95th percentile) adolescents (aged 13-18 years) were randomly assigned to the intervention (n = 39) or placebo groups.
Following a 1-month run-in period, subjects following a lifestyle intervention program were randomized 1:1 to 48 weeks' treatment with metformin hydrochloride XR, 2000 mg once daily, or an identical placebo. Subjects were monitored for an additional 48 weeks.
Main Outcome Measure
Change in BMI, adjusted for site, sex, race, ethnicity, and age and metformin vs placebo.
After 48 weeks, mean (SE) adjusted BMI increased 0.2 (0.5) in the placebo group and decreased 0.9 (0.5) in the metformin XR group (P = .03). This difference persisted for 12 to 24 weeks after cessation of treatment. No significant effects of metformin on body composition, abdominal fat, or insulin indices were observed.
Metformin XR caused a small but statistically significant decrease in BMI when added to a lifestyle intervention program.
clinicaltrials.gov Identifiers: NCT00209482 and NCT00120146
Glaser Pediatric Research Network Obesity Study Group. Metformin Extended Release Treatment of Adolescent Obesity: A 48-Week Randomized, Double-Blind, Placebo-Controlled Trial With 48-Week Follow-up. Arch Pediatr Adolesc Med. 2010;164(2):116–123. doi:10.1001/archpediatrics.2009.264
Create a personal account or sign in to: